Previous 10 | Next 10 |
Charles River Laboratories International, Inc. (NYSE: CRL) today announced a strategic agreement with Wheeler Bio, Inc., an antibody contract development and manufacturing organization (CDMO) focused on preclinical and early clinical supply of recombinant proteins, providing clients access to Whe...
The addition of ES cells and iPSCs will enhance Charles River’s portfolio of powerful research tools supporting acceleration of therapeutic development. Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an agreement with Plurist...
2024-02-16 09:06:59 ET Summary Charles River Laboratories achieved only 6.5% organic revenue growth in FY23 due to weakness in the broader life science industry. CRL offers a comprehensive range of services to pharmaceutical and biopharmaceutical companies, with a broad customer b...
2024-02-14 14:11:46 ET More on Charles River, IQVIA, etc. Charles River Laboratories International, Inc. (CRL) Q4 2023 Earnings Call Transcript Medpace Holdings, Inc. (MEDP) Q4 2023 Earnings Call Transcript Medpace Holdings, Inc. 2023 Q4 - Results - Earnings Call Pre...
2024-02-14 13:19:02 ET Charles River Laboratories International, Inc. (CRL) Q4 2023 Results Conference Call February 14, 2024 08:30 AM ET Company Participants Todd Spencer - Vice President of Investor Relations James Foster - President and Chief Executive Officer ...
2024-02-14 07:17:20 ET More on Charles River Laboratories Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation Charles River Laboratories Q4 2023 Earnings Preview Seeking Alpha’s Quant Rating on Charles River Laboratories Hi...
– Fourth-Quarter Revenue of $1.01 Billion and Full-Year Revenue of $4.13 Billion – – Fourth-Quarter GAAP Earnings per Share of $3.62 and Non-GAAP Earnings per Share of $2.46 – – Full-Year GAAP Earnings per Share of $9.22 and Non-GAAP ...
Owens Corning Inc New (OC) is expected to report $2.82 for Q4 2023 Getty Realty Corporation (GTY) is expected to report $0.56 for Q4 2023 Bion Environmental Technologies Inc. (BNET) is expected to report for Q2 2024 Nexien BioPharma Inc (NXEN) is expected to report for Q2 2024 Ayt...
2024-02-13 11:10:37 ET More on Charles River Laboratories Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation Seeking Alpha’s Quant Rating on Charles River Laboratories Historical earnings data for Charles River Laboratories ...
Endosafe ® Trillium™ recombinant cascade reagent (rCR) cartridges provide an alternative option to bolster commitments to sustainability and animal welfare Building upon its flagship Endosafe ® cartridge technology, Charles River Laboratories International, Inc....
News, Short Squeeze, Breakout and More Instantly...
Charles River Laboratories International Inc. Company Name:
CRL Stock Symbol:
NYSE Market:
2024-05-09 19:00:06 ET Elizabeth Anderson from Evercore ISI issued a price target of $265.00 for CRL on 2024-05-09 16:15:00. The adjusted price target was set to $265.00. At the time of the announcement, CRL was trading at $230.09. The overall price target consensus is a...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
– First-Quarter Revenue of $1.01 Billion – – First-Quarter GAAP Earnings per Share of $1.30 and Non-GAAP Earnings per Share of $2.27 – – Updates 2024 Guidance – Charles River Laboratories International, Inc. (NYSE: CRL) today rep...